By RealPharma
For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into bio
... more
5
88 ratings
The podcast currently has 25 episodes available.
In this conversation, Aaron Burnett, from Wheelhouse DMG, discusses the rapid evolution of digital marketing in the healthcare sector, emphasizing the importance of data strategy and compliance with regulations like HIPAA.
He highlights the shift from third-party data reliance to first-party data utilization, which enhances marketing effectiveness and patient engagement.
The discussion also covers the need for collaboration among marketing, compliance, and IT teams to develop effective data strategies and the role of customer data platforms in personalizing healthcare marketing efforts.
In this conversation, the speakers delve into the complexities of data privacy, patient consent, and the ethical implications of using AI in healthcare. They discuss the transformative role of AI and machine learning in digital health, emphasizing the importance of first-party data and the need for compelling content.
The conversation also touches on marketing strategies in a digital landscape, the evolution of media mix modeling, and the tools that enhance digital marketing efforts. Finally, the discussion concludes with an inspiring anecdote about unconventional thinking and the pursuit of personal fulfillment.
Resources:
In this latest episode of RealPharma, we’re diving back into the fascinating world of AI in pharma, breaking down all the insights from our conversation with the brilliant Andree Bates! If you missed it or want to catch the highlights, this episode serves up a concise, punchy summary covering everything from predictive analytics to patient outcomes and beyond.
But there's a twist.
Our hosts, this time, bring a unique, fresh perspective to the conversation—you might notice something different about how they tackle the topic. Stick around until the end, and you’ll find out what makes this episode truly special.
Curious? You won’t want to miss this one. Tune in, share your thoughts, and see if you can guess what’s up!
Resources
In this episode, Dr. Na-Ri Oh and Ian Wendt sit down with Philip Vyt, a renowned expert in omnichannel strategy and founder of Shyft, a consultancy specializing in omnichannel approaches for biopharma.
They delve into the key concepts behind omnichannel and its distinction from multichannel, emphasizing the centrality of healthcare professionals (HCPs) in engagement strategies. Philip breaks down the importance of personalized content delivery and the role of interconnected channels in creating a 360-degree view of HCP interactions. He also shares practical advice for biopharma companies—both large and small—on building effective omnichannel campaigns, starting with "minimal viable campaigns" to learn by doing.
The conversation explores the challenges companies face, such as managing content supply chains and the integration of technology, while highlighting the significant investments needed in marketing technology (MarTech) for a truly effective omnichannel approach. Philip also discusses the differences between the U.S. and European markets in terms of data privacy and consent, as well as the evolving role of AI and automation in real-time engagement with HCPs. Throughout, Philip provides actionable insights on how companies can avoid common pitfalls, emphasizing a focus on execution and the importance of aligning marketing with commercial excellence.
Listeners will gain a deeper understanding of what it takes to implement a successful omnichannel strategy and why it’s a journey that requires commitment, adaptation, and collaboration across teams.
Resources:
In this episode, Dr. Na-Ri and Ian Wendt welcome back Kristiaan Rawlings, from EPM Scientific to discuss the latest trends in pharma and biotech hiring.
They explore the key drivers of hiring, the impact of AI and advanced analytics, and the evolving expectations of candidates. Kristiaan emphasizes the importance of change agents in the industry and shares insights on the optimistic outlook for small biotechs and oncology. The conversation also touches on strategies for candidates to navigate career transitions and for companies to attract top talent in a competitive market.
Resources:
In this episode, Ian Wendt and Dr. Na-Ri Oh interview Michael C. Barnes, Chairman of the Center for US Policy, about the US opioid crisis.
They discuss the evolution of US policy on opioids, the impact of the crisis on different communities, the role of legislation and harm reduction, the accountability of the pharmaceutical industry, barriers to accessing treatment, and the importance of advocacy in addressing stigma.
The conversation explores various themes related to the substance use disorder crisis, including the lack of parity in insurance plans, the role of prescribers, the need for treatment and support, the potential for decriminalization, the economic impact of substance use disorders, and the US-centric nature of the problem. The guests discuss the importance of addressing substance use disorder as a health condition and providing therapeutic responses and harm reduction services. They also highlight the need for policies that focus on prevention, access to treatment, and economic opportunities for individuals in recovery. The conversation emphasizes the complexity of the issue and the need for comprehensive solutions.
Resources:
Danny McBryan, an executive leader in the pharmaceutical industry, discusses the evolving role of medical affairs in healthcare.
He highlights the importance of medical affairs in conveying the science of pharmaceutical companies and translating complex data into a meaningful narrative for healthcare providers, payers, patients, and policymakers.
McBryan emphasizes the need for medical affairs to be seen as a strategic partner rather than a support function and advocates for closer collaboration between medical affairs, health economics, and outcomes research (HEOR) to demonstrate the value of drugs and address unmet needs.
He also discusses the impact of digital transformation on medical affairs, including wearables, therapeutic digital solutions, social media, data analysis, and real-world evidence. McBryan envisions a future where medical affairs plays a more strategic role, engages with patients, and contributes to drug discovery and development.
RESOURCES
In this episode, Na-Ri and Ian interview Stacey Tinianov, an independent patient advocate and founder of Advocates for Collaborative Education.
They discuss the importance of patient advocacy, the role of digital health, and the future of patient engagement.
Stacey shares her personal journey into patient advocacy and highlights the gaps in knowledge and understanding she experienced as a breast cancer survivor. She emphasizes the need for human-centered design in healthcare, where patients are at the center of the design, development, and deployment of programs and technologies.
Stacey also discusses the impact of digital platforms on patient engagement and the importance of building relationships and engaging with patients beyond a transactional level. Patient advocacy is a multifaceted field that encompasses various areas, including clinical trial advocacy, research advocacy, and policy advocacy. The future of patient advocacy lies in the expansion of voices and the focus on improving quality of life and survivorship. Advocates play a crucial role in shaping clinical trials, ensuring patient-reported outcomes are considered, and driving policy changes. The ultimate goal is to achieve true partnerships between advocacy and industry, as well as the decentralization of clinical trials.
Patient advocates can effectively communicate by understanding their motivation and goals and tailoring their language to resonate with different stakeholders. The consequences of not getting patient advocacy right include a regression to the frustrating relationship patients had with pharmaceutical companies in the past. However, progress has been made, and patient advocacy has the potential to drive positive change in healthcare.
Resources:
Summary
Dr. Andrée Bates, a pioneering force in the realm of artificial intelligence within the pharmaceutical industry, shares insights on the evolving role of AI in pharma, the future of healthcare innovation, and her advocacy for women in leadership.
She discusses the early days of AI in pharma, the challenges faced, and the evolution of AI terminology. Dr. Bates also explores the application of AI in commercial insights and analytics, market access, drug discovery, and clinical trials.
The conversation covers a wide range of topics related to the application of AI in the biopharma industry, including the use of synthetic data, digital twins, regulatory and medical affairs, market access, precision doctor targeting, and ethical implications.
Dr. Andree Bates shares insights on the impact of AI on drug discovery, clinical trials, and patient care, as well as the potential for AI to revolutionize the industry.
Resources
Summary
In this episode, Dr. Na-Ri Oh and Ian Wendt discuss Pharmacy Benefit Managers (PBMs) and their impact on drug pricing and patient access to medications.
They are joined by Antonio Ciaccia, CEO of 46 Brooklyn Research and president of 3 Access Advisors, which provides insights into the role of PBMs in the drug supply chain.
The conversation highlights the consolidation of power among the top three PBMs, their anti-competitive behaviors, and the need for increased scrutiny and regulatory measures. The discussion also explores the distorted incentive structures that favor high-cost drugs over lower-cost alternatives, leading to higher drug costs and limited access for patients.
The conversation explores the impact of pharmacy benefit managers (PBMs) on drug costs and access to medications. The report states that PBMs control about 70% of all specialty drug revenue, leading to the closure of independent retail pharmacies in rural areas. The conversation emphasizes the need for transparency and accountability in the PBM industry.
It also discusses the potential solutions, including market-based approaches and policy changes, to address the inefficiencies and anti-competitive behaviors of PBMs.
Resources
In this episode, Dr. Na-Ri Oh and Ian Wendt discuss the 340B drug pricing program with guest William Sarraille, a healthcare law expert.
They explore the origins of the program and its intended purpose. However, the program has grown exponentially and is now the second largest drug program in the country. Bill raises concerns about the lack of transparency and accountability in the program, as well as the impact on patients. He argues that the program should focus on delivering value to patients and ensuring that they benefit from the discounts.
The conversation delves into the complexities and challenges of the 340B program, highlighting issues such as the patient definition, transparency, contract pharmacies, and the allocation of funds. The discussion considers the need for a more comprehensive and transparent system that ensures the benefits of the program flow to the patients. They also explore the possibility of implementing a claims data process that provides faster payment and greater certainty for both manufacturers and 340B entities.
The conversation concludes with a reflection on the importance of leadership and collaboration in finding solutions to the program's problems.
Resources:
The podcast currently has 25 episodes available.
1,909 Listeners
32,046 Listeners
43,197 Listeners
3,092 Listeners
7,999 Listeners
3,059 Listeners
111,405 Listeners
452 Listeners
305 Listeners
372 Listeners
776 Listeners
4,424 Listeners
7,646 Listeners
56,910 Listeners
143 Listeners